NCT07477158 Clinical Outcomes and Quality Of Life After Minimally Invasive Segmentectomy Versus Lobectomy for Lung Cancer
| NCT ID | NCT07477158 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal |
| Condition | Non Small Cell Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 180 participants |
| Start Date | 2023-07-10 |
| Primary Completion | 2027-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 180 participants in total. It began in 2023-07-10 with a primary completion date of 2027-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal is to compare patient reported outcomes, such as dyspnea, physical functioning and quality of life, between minimally invasive segmentectomy and lobectomy for stage I NSCLC during the first year after surgery. The main questions it aims to answer are: * Do patients with stage I NSCLC that undergo minimally invasive segmentectomy have less postoperative dyspnea than patients that undergo lobectomy? * Do patients with stage I NSCLC that undergo minimally invasive segmentectomy have more favorable postoperative health related quality of life (HRQoL) than patients that undergo lobectomy? * Do patients with stage I NSCLC that undergo VATS segmentectomy or lobectomy have more favorable postoperative health related quality of life (HRQoL) than patients that undergo RATS segmentectomy or lobectomy? Participants already undergoing surgical intervention as part of their regular medical care for resectable lung cancer will answer quality of life questionnaires preoperatively, at 1, 3, 6, and 12 months after surgery.
Eligibility Criteria
Inclusion Criteria: * Patients with clinical stage I NSCLC who undergo segmentectomy or lobectomy with VATS or RATS. Exclusion Criteria: * Thoracic surgery in the previous year * Neoadyuvant treatment * Failure to complete preoperative questionnaires
Contact & Investigator
Sara Fra, MD
PRINCIPAL INVESTIGATOR
Hospital Universitario Ramon y Cajal
Frequently Asked Questions
Who can join the NCT07477158 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Non Small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07477158 currently recruiting?
Yes, NCT07477158 is actively recruiting participants. Contact the research team at sarafrafernandez@gmail.com for enrollment information.
Where is the NCT07477158 trial being conducted?
This trial is being conducted at Madrid, Spain.
Who is sponsoring the NCT07477158 clinical trial?
NCT07477158 is sponsored by Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal. The principal investigator is Sara Fra, MD at Hospital Universitario Ramon y Cajal. The trial plans to enroll 180 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.